Magenta reports results from MGTA-145 stem cell mobilization program
Magenta Therapeutics announced that new results from its MGTA-145 stem cell mobilization program were presented at the Annual Meeting of the American Society of Hematology. These results showed that MGTA-145 in combination with plerixafor met all the endpoints in the study, and safely mobilized a large number of high-quality stem cells in a single day, the company said. The cells were then shown to engraft in a humanized mouse model. Magenta is developing MGTA-145 as the new first-line standard of care for stem cell mobilization in a broad range of diseases, including autoimmune diseases and genetic diseases. MGTA-145, a CXCR2 agonist, works in combination with plerixafor, a CXCR4 antagonist, to harness the physiological mechanism of stem cell mobilization. MGTA-145 was safe and well-tolerated as a single agent and in combination with plerixafor and showed the expected target pharmacology, Magenta said. Five of six subjects who received a single dose of the combination of MGTA-145 at the .03 dose level and plerixafor mobilized more than 20 CD34+ cells/microliter, the clinically accepted threshold for successful mobilization, in a single day. The median percentage of CD34+CD90+ cells was 33%, compared to approximately 10% with G-CSF-mobilized peripheral blood.